Who to call at Apimeds Pharmaceuticals US, and when
Fundz watches for the moments Apimeds Pharmaceuticals US starts buying, and tells you who to reach.
- An alert the day Apimeds Pharmaceuticals US raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Apimeds Pharmaceuticals US, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Apimeds Pharmaceuticals US. With Fundz connected, it knows.
Contract Type
assignment_agreement
Description
On August 19, 2026, Apimeds Pharmaceuticals US, Inc. signed an Assignment and Transfer Agreement with FreeT Inc., acquiring specific Apitox-related rights. This agreement allows Apimeds to take over all interests that FreeT had under the previous Apitox Rights Transfer Agreement from 2015. The Assigned Rights include complete ownership of these rights, which strengthens Apimeds' portfolio in the pharmaceutical sector.
Quick answer
Apimeds Pharmaceuticals Enters into Assignment Agreement with FreeT Inc. (August 21, 2026). Apimeds Pharmaceuticals US is based in Matawan, New Jersey, United States.
- What agreement did Apimeds Pharmaceuticals US announce on August 21, 2026?
- On August 19, 2026, Apimeds Pharmaceuticals US, Inc. signed an Assignment and Transfer Agreement with FreeT Inc., acquiring specific Apitox-related rights. This agreement allows Apimeds to take over all interests that FreeT had under the previous Apitox Rights Transfer Agreement from 2015.
- What does Apimeds Pharmaceuticals US do?
- Apimeds is a clinical-stage biopharmaceutical company developing Apitox, an intradermally administered honeybee venom-based toxin.
- Where is Apimeds Pharmaceuticals US based?
- Apimeds Pharmaceuticals US is based in Matawan, New Jersey, United States.
Source: Fundz verified event record.
Related People
Apimeds Pharmaceuticals US signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.